On October 18, 2010, an FDA advisory panel considered data from the TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) and the implications of the results in dosing the drug in patients with anemia associated with chronic renal failure in patients not yet on dialysis.
All Comments